Clinical Trial

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

Study acronym: EXPEDITION
Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2023-07-21; most recent amendment 2026-02-04.
Status change: Not Yet Recruiting → Enrolling by Invitation 2023-10-26
Trial Details
NCT Number NCT05967351
Lead Sponsor Sarepta Therapeutics, Inc.
Collaborators: Hoffmann-La Roche
Conditions Duchenne Muscular Dystrophy
Enrollment 400 participants
Start Date 2023-09-27
Primary Completion 2033-10-31 (estimated)
Study Completion 2033-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-06